Press releases

2020

2020-06-26 13:30 SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue Regulatory MAR
2020-06-18 15:30 Wider range of prospective patients in the UK, Canada and the US for continued clinical study Regulatory
2020-06-16 18:19 A future alternative to hormonal treatment for prostate cancer Regulatory
2020-06-01 19:54 Subscription period postponed for the rights issue. Other conditions remain unchanged Regulatory
2020-06-01 14:12 Patent application submitted to protect new technology Regulatory
2020-06-01 13:45 SpectraCure's MSEK 140 rights issue of units is fully guaranteed Regulatory MAR
2020-05-28 14:45 SpectraCure AB Quarterly Report (1 Jan to 31 March) 2020 Regulatory MAR
2020-04-07 10:00 Patent application enters PCT phase, SpectraCure ensures development and work Regulatory MAR
2020-03-16 13:15 New study underway in the US and approval from the Food and Drug Administration (FDA) Regulatory MAR
2020-03-12 11:35 The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020 Regulatory
PreviousNext